MedPath

Inavolisib

Generic Name
Inavolisib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H19F2N5O4
CAS Number
2060571-02-8
Unique Ingredient Identifier
L4C1UY2NYH
Background

Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study Evaluating Single-agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Phase 1
Recruiting
Conditions
PIK3CA-Mutated Cancers
Interventions
Drug: Inavolisib
Drug: Atezolizumab
First Posted Date
2024-07-11
Last Posted Date
2025-01-03
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT06496568
Locations
🇺🇸

Moores Cancer Center at UC San Diego Health, La Jolla, California, United States

🇺🇸

California Cancer Associates for Research & Excellence, Inc., San Marcos, California, United States

🇺🇸

Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States

and more 5 locations

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 3
Recruiting
Conditions
Metastatic Breast Cancer
Interventions
Drug: Inavolisib
Drug: Taxane-based Chemotherapy
Drug: Phesgo
Drug: Placebo
Drug: Optional Endocrine Therapy of Investigator's Choice
First Posted Date
2023-06-08
Last Posted Date
2024-12-31
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
230
Registration Number
NCT05894239
Locations
🇺🇸

Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Ellison Institute of Technology, Los Angeles, California, United States

and more 156 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1
Recruiting
Conditions
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Interventions
Drug: Giredestrant
Drug: Ribociclib
Drug: PH FDC SC
Drug: Abemaciclib
Drug: Ipatasertib
Drug: Inavolisib
Drug: Everolimus
Drug: Samuraciclib
Drug: Atezolizumab
Drug: Palbociclib
First Posted Date
2021-03-17
Last Posted Date
2025-01-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
510
Registration Number
NCT04802759
Locations
🇺🇸

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

🇮🇱

Rabin MC, Petach Tikva, Israel

🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 25 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Cancer
Advanced Solid Tumors
Colorectal Cancer
Interventions
Drug: GDC-6036
Drug: Erlotinib
Drug: Cetuximab
Drug: Atezolizumab
Drug: Bevacizumab
Drug: GDC-1971
Drug: Inavolisib
First Posted Date
2020-06-29
Last Posted Date
2025-01-06
Lead Sponsor
Genentech, Inc.
Target Recruit Count
498
Registration Number
NCT04449874
Locations
🇺🇸

Univ of Calif, San Francisco, San Francisco, California, United States

🇺🇸

University of Oklahoma, Oklahoma City, Oklahoma, United States

🇺🇸

Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 70 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy